Harvard Bioscience Still Rocking From Genomic Solutions Crash | GenomeWeb

A year ago, Harvard Bioscience was on the fast track to growth. The company was growing revenues and expanding its reach through a series of acquisitions that created a diverse portfolio of companies providing tools to basic research, the clinical market, and drug discovery.

The stock price of the Holliston, Mass.-based laboratory equipment company grew to a high of $10.73 on Feb. 18, 2004, from a low of $3.00 on April 10, 2003.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.